Cargando…

Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico

Amyloid-beta peptides have long been implicated in the pathology of Alzheimer’s disease. Bexarotene, a drug approved by the U.S. Food and Drug Administration for treating a class of non-Hodgkin’s lymphoma, has been reported to facilitate the removal of amyloid-beta. We have developed a mathematical...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, Joseph, Belfort, Georges, Isaacson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830620/
https://www.ncbi.nlm.nih.gov/pubmed/27073866
http://dx.doi.org/10.1371/journal.pone.0153150